Salvat Laboratories presented Phase III clinical trials results of Clobetasol Nanoemulsion for treating inflammation and pain after ocular surgery at the 2023 ARVO Annual Meeting
Salvat, the international laboratory that has developed and owns Cristalmina, Gama Relive, Tebarat and Cetraxal products, has submitted the NDA documentation for a new drug application to the U.S. Food and Drug Administration (FDA) for approval of Clobetasol, the first ocular corticosteroid formulated in a nanoemulsion for inflammation and pain in patients undergoing eye surgery.
Salvat is gearing up to launch an ocular corticosteroid treatment for inflammation and pain in cataract surgery patients after finishing phase 3 trials and starting the approval process in the U.S. and Europe.
Salvat is gearing up to launch an ocular corticosteroid treatment for inflammation and pain in cataract surgery patients after finishing phase 3 trials and starting the approval process in the U.S. and Europe.
This Pharmaceutical and Healthcare pipeline guide, Glaucoma Pipeline Review, H1 2020 provides comprehensive information on the therapeutics under development for Glaucoma (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
This Pharmaceutical and Healthcare pipeline guide, Glaucoma Pipeline Review, H1 2020 provides comprehensive information on the therapeutics under development for Glaucoma (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Le Produits BFS (Blow-Fill-Seal) rapport d’analyse de marché mondial 2020 est une étude de recherche omniprésente, qui fournit les détails techniques et financiers actuels et à venir de l’industrie Produits BFS (Blow-Fill-Seal), qui vous aideraient à gérer votre entreprise plus efficacement. Le rapport présente des données cruciales sur le marché telles que les tendances clés du marché, les Produits BFS (Blow-Fill-Seal) facteurs de croissance des entreprises, les moteurs, les menaces commerciales, le paysage concurrentiel, la dynamique du marché et les opportunités pour les acteurs établis ou les nouveaux arrivants sur le marché mondial Produits BFS (Blow-Fill-Seal). Cette analyse de marché d’une industrie est cruciale pour diverses parties prenantes telles que les investisseurs, les PDG, les commerçants, les fournisseurs et autres associés à l’activité Produits BFS (Blow-Fill-Seal).
Again this year, Laboratorios Salvat, S.A. has been granted with the rating “VERY GOOD” by the PROFARMA 2019 program of the Spanish Ministry of Industry, which values pharmaceutical companies based on their excellence in Industrial, economic and Research, Development and Innovation activities. This qualification represents an important recognition of Salvat’s continued efforts towards its objective of providing innovative treatments to the therapeutic arsenal of the medical community, both Spanish and international.
Salvat, laboratory that manufactures products such as Cristalmina, Monolitum, Relive, Levogastrol and Cetraxal, expects the approval and launch of the first topical medicament for the treatment of otomycosis in just over a year in USA and Europe. This commitment reinforces Salvat’s position as a world leader in the field of otology.
El lanzamiento mundial del nuevo medicamento para tratar este tipo de otitis externa, previsto para finales de 2021, refuerza el posicionamiento de la compañía en otología a nivel internacional.